stockrow
Monday 9 November 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROSKeros Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $244.1 million, up 6,775.0% from fiscal 2024.
- Revenue
- +120.2%
- EPS
- +494.4%
- Free cash flow
- +6.87%
Quarter to September 2026, against a year earlier
9.36
0.09
−0.95%
Follow KROS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 4 | — | 3 |
| 19.90% | (16.79%) | (17.16%) | (12.56%) | ||
| 18.24% | (15.53%) | (15.92%) | (11.76%) | ||
ROIC |
268.69% | (1,668.70%) | (1,345.30%) | (233.22%) | |
Return on Tangible Assets |
29.07% | (30.22%) | (32.18%) | (22.43%) | |
Average Days of Receivables |
8.70 | 29.15 | 0.00 | 0.00 | |
Free Cash Flow per Share |
2.85 | (2.97) | (2.45) | (2.43) | |
Free Cash Flow |
105.95 | (58.25) | (48.49) | (48.27) | |
Capital Expenditures |
(1.55) | (1.06) | (0.49) | (0.42) | |
| Other line items | |||||
Cash ROIC |
17.94% | (10.27%) | (9.33%) | (8.96%) | |
Accounts Receivable Turnover |
57.03 | 3.33 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.05) | 0.00 | 0.00 | (0.07) | |
Research and Development Expense of Revenue |
53.12% | 292.42% | 0.00% | 139.63% | |
Selling, General and Administrative Expense of Revenue |
19.20% | 140.13% | 0.00% | 67.60% | |
Share Based Compensation of Revenue |
11.76% | 78.45% | 0.00% | 41.95% | |
Operating CF/Net income |
1.24 | 0.67 | 0.58 | 0.78 | |
Depreciation/Fixed assets |
0.35 | 0.40 | 0.43 | 0.47 | |
Capex/Depreciation |
(1.03) | (0.68) | (0.31) | (0.26) | |
Revenue per Share |
6.56 | 1.69 | 0.00 | 2.77 | |
Operating CF per Share |
2.89 | (2.91) | (2.42) | (2.41) | |
Capex per Share |
(0.04) | (0.05) | (0.02) | (0.02) | |
Capex to Sales |
0.01 | 0.03 | 0.00 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026